Background: Various drugs are effective in the management of painful diabetic neuropathy, but none is completely satisfactory. We previously found sodium valproate to be effective and safe in a short-term study. Aim: To test the effectiveness and safety of sodium valproate in the management of painful diabetic neuropathy over 3 months. Design: Randomized double-blind placebocontrolled study. Methods: Consecutive attending patients with type 2 diabetes mellitus with painful neuropathy were asked to participate in the trial: 48 agreed. Five were excluded: three with HbA 1c > 11, one with too low a pain level and one who withdrew consent. The remaining 43 were given either drug (group A) or placebo (group B). Each patient was assessed clinically. Quantitative assessment of pain was done by McGill Pain Questionnaire,
Introduction
Diabetic neuropathy is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in a patient with diabetes, after the exclusion of other causes. 1 In the course of diabetes, some 20%-90% of individuals eventually develop diabetic neuropathy. 2 The aetiological factors attributed to diabetic neuropathy can be grouped into those having a definite role (e.g. poor glycaemic control, duration of disease) and those with a probable added influence (e.g. hypertension, age, smoking, hyperinsulinaemia, dyslipidaemia). [3] [4] [5] [6] [7] Painful diabetic neuropathy requires medical attention because of its adverse effect on quality of life. The important drug interventions in its management include non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressants and anti-epileptic drugs, [8] [9] [10] but there are problems with side-effects and contraindications for all these drugs. Other drugs used for pain relief have include clonazepam, gabapentine, lamotrigine, baclofen, i.v. lidocaine or mexiletine, aldose reductase inhibitors, gammalinolinic acid, nucleosides, nerve growth factor and capsaicin-containing ointments, but none is entirely satisfactory.
Sodium valproate, which has proved to be effective in trigeminal neuralgia and migraine prophylaxis, 10 has also shown significant role in the subjective improvement of painful diabetic neuropathy, with a unique advantage of low toxicity and favourable side effect profile. 11 In an earlier study, 11 we observed a significant subjective improvement in painful diabetic neuropathy in patients receiving sodium valproate in comparison to placebo at the end of one month. Because that was a short-term study, we began a fresh one in January 2002 to study the usefulness and safety profile of this drug over a longer period in the management of painful diabetic neuropathy.
Methods Patient and control selection
A consent form explaining the nature of the study in detail was given to consecutively attending patients of diabetes mellitus with painful neuropathy, and the first 48 patients were included in the trial and asked to attend on a specific date. Five patients were not included in the study: three had HbA 1c > 11, one had too low a pain score (Visual Analogue Scale < 4), and one patient withdrew consent; thus 43 patients were followed up for 3 months. The medications offered to the patients were given in packets containing sufficient drug to last for 3 months, bearing a distinctive code number. All patients were subjected to thorough interview, clinical examination and relevant laboratory investigations. All were asked to fill in (by themselves or with assistance) a short-form McGill pain questionnaire (SF-MPQ), visual analogue score (VAS) and present pain intensity (PPI), first initially, then after 1 month and then 3 months. Biochemical examinations, which included urinalysis, fasting blood sugar, HbA 1c , lipid profile and liver function tests (serum bilirubin, AST, ALT) were done at the beginning of the study. Liver function test and blood sugar were studied on every subsequent visit to check glycaemic control and to rule out any hepatotoxicity of sodium valproate.
Depending on the specific code number, the patients received either 500 mg (one tablet) of sodium valproate once a day, or similar type of placebo one tablet once a day. At the end of one week, leading questions were asked for sodium valproate toxicity in the form of nausea and vomiting, and the patients were examined for detailed neurological examination, specially nystagmus and ataxia. Serum AST/ALT was done in all the patients, and patients having normal values were subsequently put on one tablet two times a day for remaining three months. Patients who showed signs of intolerance did not continue in the study.
A specific member of research project was responsible for the administration of drug or placebo. Clinical evaluation, nerve conduction study and pain scoring was done by another member of the team, who was completely blinded to the drug status. All the data, along with code numbers, were submitted to the statistician, and after decoding, the patients were divided into group A (receiving drug) and Group B (receiving placebo). All patients were kept euglycemic by diet alone, OHA, OHA þ insulin or insulin alone. None of the patients were allowed to take analgesics for control of pain. 
Selection criteria

Exclusion criteria
Patients suffering from liver disease, pulmonary tuberculosis, thyroid disorders, uraemia, vitamin deficiency, hereditary and paraneoplastic neuropathy, alcoholism, or patients on steroid therapy, were not included after relevant clinical and biochemical examination.
Laboratory studies
Fasting blood sugar estimation was by the glucose oxidase method. Glycated haemoglobin (HbA 1c ) of each patient was measured by high-performance liquid chromatography. Electrophysiological studies, in the form of motor (MNCV) and sensory (SNCV) nerve conduction studies, were performed at the beginning of the study and after 3 months in patients of both groups. All recording sessions for MNCV and SNCV were in a shielded, partially soundproof chamber. MNCV was done in the median, ulnar, peroneal and posterior tibial nerves on both sides. Sensory nerve conduction velocity was done in the median nerve of both sides in upper limbs and in the sural nerve in the lower limb.
Statistical analysis
The demographic characteristics and data of the two groups were comparable (Table 1) . All values (e.g. fasting blood glucose, HbA 1c , albuminuria) were expressed as means AE SEM. The responses to drugs were compared statistically in relation to painful diabetic neuropathy (0, 1 month, 3 months). Data comparisons between the groups were by ANOVA, and post hoc comparisons by Tukey's HSD for unequal n. Figure 1 shows the flow of patients through the study. Changes in pain score from baseline to end of treatment (assessed by SF-MPQ, VAS and PPI) are shown in Table 2 . Differences between sodium valproate and placebo group were significant at the endpoint for all three scores, both at the end of one month and after three months.
Results
Clinical data
In group A (the drug group), initial mean SF-MPQ was 19.47 AE 6.79, falling to 9.66 AE 5.96 (p < 0.001) after 3 months. Similarly, mean VAS fell from 6 AE 1.95 (baseline) to 3 AE 2.12 (3 months) (p < 0.001), and mean PPI from 2.71 AE 1.00 (baseline) to 1.33 AE 0.66 (3 months) (p < 0.001). These variables did not change significantly over the same period in the placebo group (Figures 2, 3 and 4 , Table 2 ).
Electrophysiological data are shown in Table 3 . There were no statistically significant differences between the groups, either initially or after 3 months, neither group showing any improvement over the study course.
Safety profile
Of the 22 patients who received the drug, two developed nausea, and one developed minor drowsiness, which had disappeared by the next visit. Only one patient showed a major side-effect, in the form of deranged liver function tests (serum bilirubin 3 mg%, AST 120 U/l, ALT 124 U/l) at one month, and was removed from the study. All other patients tolerated the drug well ( Table 4 ). The 21 patients receiving placebo had no side-effects.
Discussion
Painful diabetic neuropathy significantly affects the quality of life, so far no ideal drug has been available for its management. In the absence of curative therapy, the main aim of management is to provide symptomatic pain control using pharmacological and non-pharmacological agents, and to preserve good glycaemic control. Pharmacological therapy includes tricyclic antidepressant, narcotic analgesics, anticonvulsants and anti-arrhythmic drugs, but adverse effects have limited the effectiveness of these agents. 9 Double-blind trials of the tricyclic antidepressant amitriptyline have demonstrated significant benefits in reducing burning, aching, sharp, throbbing, and stinging pain. 9 This dose-dependent effect is independent of mood elevation. 10 However, the use of amitriptyline in patients with heart block, urinary tract obstruction, orthostatic hypotension, or narrow-angle glaucoma, is contraindicated. Diphenyl hyndantoin which is commonly used in the management of painful neuropathy, 12 was found to be of no significant value in a double-blind crossover study. 13 In three controlled, double blind studies, carbamazepine was shown to be of value in painful diabetic neuropathy, but because its potential toxicity, its use is limited. [14] [15] [16] Other drugs in use for pain relief are clonazepam, baclofen, i.v. lidocaine or mexiletine, aldose reductase inhibitors, gamma linolenic acid, nucleosides, nerve growth factors and capsaicincontaining ointment. [17] [18] [19] [20] [21] The use of these drugs for long duration in painful diabetic neuropathy is limited because of their adverse side effects. Capsaicin-containing ointments produce initial irritation, which is too unpleasant for continuous use. 22 Gabapentin has been shown to be more effective then placebo in doses ranging from 900 to 3600 mg/day. 23 The lower end of this dose range may be relatively ineffective. The main side-effects of gabapentin are dizziness, somnolence, headache, diarrhoea, confusion and nausea. 23 We previously observed a significant subjective improvement in painful diabetic neuropathy in patients receiving sodium valproate in comparison to placebo at the end of one month, 11 and unlike other anti-epileptic drugs, it has a favourable side effect profile. 8 This study tested the efficacy and safety of sodium valproate over a period of 3 months.
At the end of the study, there was a statistically significant reduction in pain score values (SF-MPQ, VAS and PPI) in patients treated with sodium valproate, compared to placebo. Motor and sensory nerve conduction velocities, which were deranged in the beginning of study in diabetic patients of both groups showed no improvement after 3 months. Similar findings were observed in the earlier study.
11
Sodium valproate probably acts by potentiating the inhibitory transmitter g-aminobutyric acid (GABA), and has been shown to prevent its degradation and neuronal uptake, without altering the response to exogenously applied GABA. 24 Sodium valproate increases brain GABA levels, and in doing so, may suppress migraine-1-related events in the cortex. 24 There is experimental evidence that it suppresses neurogenic inflammation and directly attenuates nociceptive neurotransmission. 25 In addition, valproate reportedly alters levels of excitatory and inhibitory neurotransmitters, and exerts direct effect on neuronal membranes in vitro. 25 These observed effects may ultimately result from a combination of actions at different loci. Its mechanism of action in pain relief is not yet fully defined.
To conclude, our study shows a useful role of sodium valproate in the management of painful diabetic neuropathy, assessed by three different pain scores (SF-MPQ, VAS and PPI), and the drug was well-tolerated by our patients. 
